Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
May 24 2023 - 06:35AM
Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing
therapeutics based on synthetic biology, today announced its
planned presentations at the 2023 Synthetic Biology: Engineering,
Evolution & Design (SEED) conference being held May 30 – June
2, 2023 in Los Angeles, CA. The company’s oral presentation focuses
on Synlogic’s development of a Synthetic Biotic drug candidate for
the potential treatment of homocystinuria (HCU), a rare metabolic
disease caused by an inborn error of metabolism. The company’s
poster presentations highlight preclinical and clinical data.
Presentation details are provided below.
“The data being presented by our team at SEED this year
showcases the extraordinary progress our Synthetic Biotic platform
has achieved across multiple therapeutic categories,” said Dave
Hava, Chief Scientific Officer and Head of Research and Development
at Synlogic. “These presentations highlight the application of
synthetic biology in creating a new class of biotherapeutics, which
we hope will provide new treatment options for patients in
need.”
Oral Presentation:
- Title: A
Genetically-Engineered Probiotic Designed to Consume Methionine for
the Treatment of Homocystinuria
- Author: Analise
Reeves, PhD, Synlogic
- Date and Time:
Thursday, June 1, 2023 at 3:45 P.M. PDT
- Session: Microbiome
Engineering for Health, Food, and the Environment
Poster Presentations:
- Title: Robust
Performance and Rapid Construction of Live Bacterial Therapeutics
Lacking the Colibactin Gene Cluster
- Author: Jaclyn
Thompson, Synlogic
- Date and Time:
Tuesday, May 30, 2023 from 4-5:30 P.M. PDT
- Poster Number:
38A
- Title: Engineering
Synthetic Biotics to Secrete Therapeutic Proteins
- Author: Jian-Rong
Gao, MS, Synlogic
- Date and Time:
Wednesday, May 31, 2023, from 5-6:30 P.M. PDT
- Poster Number:
51B
- Title: SYNB1353, a
Synthetic Biotic Engineered for the Treatment of HCU, Metabolizes
Methionine and Lowers Homocysteine in Preclinical and Clinical
Models
- Author: Jillian
Means, MS, Synlogic
- Date and Time:
Thursday, June 1, 2023 from 5-6:30 P.M. PDT
- Poster Number:
51C
The presentations will be available in their respective sections
of the Publications page on the Synlogic website on the day of
the presentations.
About Synlogic
Synlogic is the leading company advancing therapeutics based on
synthetic biology. Synlogic’s pipeline includes its lead program in
phenylketonuria (PKU), which has demonstrated proof of concept with
plans to start a pivotal, Phase 3 study in the first half of 2023,
and additional novel drug candidates designed to treat
homocystinuria (HCU), enteric hyperoxaluria and gout. The rapid
advancement of these potential biotherapeutics, called Synthetic
Biotics, has been enabled by Synlogic’s reproducible,
target-specific drug design. Synlogic uses programmable,
precision genetic engineering of well-characterized probiotics to
exert localized activity for therapeutic benefit, with a focus on
metabolic and immunological diseases. In addition to its clinical
programs, Synlogic has a research collaboration with
Roche on the discovery of a novel Synthetic Biotic for the
treatment of inflammatory bowel disease or IBD. Synlogic has also
developed two drug candidates through a research collaboration with
Ginkgo Bioworks: SYNB1353, designed to consume methionine for the
potential treatment of HCU, and SYNB2081, designed to lower uric
acid for the potential treatment of gout. For additional
information visit www.synlogictx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, clinical development plans, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. In addition, when or
if used in xthis press release, the words "may," "could," "should,"
"anticipate," "believe," “look forward,” "estimate," "expect,"
"intend," on track,” "plan," "predict," “prepare” and similar
expressions and their variants, as they relate to Synlogic,
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's approach
to Synthetic Biotics to develop therapeutics to address a wide
range of diseases including: inborn errors of metabolism and
inflammatory and immune disorders; our expectations about
sufficiency of our existing cash balance; the future clinical
development of Synthetic Biotics; the
approach Synlogic is taking to discover and develop novel
therapeutics using synthetic biology; and the expected timing
of Synlogic's clinical trials of SYNB1934, SYNB1353,
SYNB8802 and SYNB2081 and availability of clinical trial data.
Actual results could differ materially from those contained in any
forward-looking statements as a result of various factors,
including: the uncertainties inherent in the clinical and
preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the U.S. Securities and
Exchange Commission. The forward-looking statements contained in
this press release reflect Synlogic's current views with
respect to future events. Synlogic anticipates that
subsequent events and developments will cause its views to change.
However, while Synlogic may elect to update these
forward-looking statements in the
future, Synlogic specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing Synlogic's view as of any date subsequent
to the date hereof.
----
Media Contact: media@synlogictx.com
Investor Relations: investor@synlogictx.com
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Synlogic (NASDAQ:SYBX)
Historical Stock Chart
From Mar 2023 to Mar 2024